Tyra Biosciences Inc
For the period ended Dec 31, 2023. Filed Mar 19, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 19, 2024
TYRA$21.15+1.2%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · AdditionalPaid-InCapital · Accumulated Other Comprehensive Loss · AccumulatedDeficit · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance at December 31, 2021 | 41,441,135 | $4 | $342,104 | $— | $(40,371) | $301,737 |
| Issuance of common stock for stock option exercises | 98,276 | — | 632 | — | — | 632 |
| Vesting of shares of common stock subject to repurchase | 814,139 | — | 197 | — | — | 197 |
| Stock-based compensation | — | — | 10,588 | — | — | 10,588 |
| Net loss | — | — | — | — | (55,325) | (55,325) |
| Balance at December 31, 2022 | 42,353,550 | $4 | $353,521 | $— | $(95,696) | $257,829 |
| Issuance of common stock under benefit plans | 464,596 | — | 1,537 | — | — | 1,537 |
| Vesting of shares of common stock subject to repurchase | 206,488 | — | 124 | — | — | 124 |
| Stock-based compensation | — | — | 13,525 | — | — | 13,525 |
| Unrealized gain on marketable securities available-for-sale, net | — | — | — | 381 | — | 381 |
| Net loss | — | — | — | — | (69,134) | (69,134) |
| Balance at December 31, 2023 | 43,024,634 | $4 | $368,707 | $381 | $(164,830) | $204,262 |
State
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.